The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03475953
Recruitment Status : Recruiting
First Posted : March 23, 2018
Last Update Posted : March 3, 2023
Sponsor:
Collaborators:
Bayer
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Institut Bergonié

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2025
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):